IKNA Insider Trading - Ikena Oncology, Inc.

Insideraktier

3.523.397 shares

Insider-stemningsscore

Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.

Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.

Se Højest rangerende aktier

Officers sentiment score

Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.

Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.

Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.

Opdateringsfrekvens: Dagligt

Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.

Se Højest rangerende aktier

Nøgle Insider Metrics

Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.

For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).

Netto antal insidere, der køber (rang)

N/A

Netto antal insidere, der køber, er det samlede antal insiders, der køber minus det samlede antal insiders, der har solgt inden for de sidste 90 dage. Percentilrangen vises her (spænder fra 0 til 100%).

Procent af float købt af insidere (rangering)

N/A

Procent af float købt af insidere er det samlede antal aktier købt af insidere minus det samlede antal aktier solgt af insidere inden for de sidste 90 dage, divideret med den samlede float og ganget med 100.

Insiderhandelsdiagram

Ikena Oncology, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.

Insiderliste og lønsomhedsmålinger

Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.

See our leaderboard of most profitable insider traders.

Insider	Gennemsnitlig fortjeneste (%)	Aktier Ejet	Dele Justeret

Report errors via our new Insider Auditing Tool

Track Records af insiderkøb - Kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i IKNA / Ikena Oncology, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Maks
2025-12-24	SLATTERY JOSEPH P	16.000	5,9900	16.000	5,9900	95.840	0
2025-07-25	Stampacchia Otello	267.556	29,9000	267.556	29,9000	7.999.924
2025-07-25	Bonita David P	83.611	29,9000	83.611	29,9000	2.499.969
2022-06-24	Bonita David P	65.965	4,3700	5.497	52,4400	288.267
2022-06-24	Bonita David P	96.035	5,3700	8.003	64,4400	515.708
2022-06-24	ORBIMED ADVISORS LLC	96.035	5,3700	8.003	64,4400	515.708
2022-06-24	ORBIMED ADVISORS LLC	65.965	4,3700	5.497	52,4400	288.267
2022-06-23	Bonita David P	23.419	3,7100	1.952	44,5200	86.884
2022-06-23	ORBIMED ADVISORS LLC	23.419	3,7100	1.952	44,5200	86.884

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IKNA / Ikena Oncology, Inc. Insider Trades

Track Records af insidersalg - Kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i IKNA / Ikena Oncology, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato	Insider	Rapporteret Aktier	Rapporteret Pris	Justeret Aktier	Justeret Pris	Omkostningsgrundlag	dage til Min	Pris kl Min	Max tab Undgået ($)	Max tab Undgået (%)
2021-12-14	Atlas Venture Fund XI, L.P.	5.959	14,0000	497	168,0000	83.426	337	2.0000	-82.434	-98,81
2021-12-14	FORMELA JEAN FRANCOIS	5.959	14,0000	497	168,0000	83.426
2021-12-13	Atlas Venture Fund XI, L.P.	8.330	14,6400	694	175,6800	121.951
2021-12-13	FORMELA JEAN FRANCOIS	8.330	14,6400	694	175,6800	121.951
2021-12-10	Atlas Venture Fund XI, L.P.	11.989	15,0300	999	180,3600	180.195
2021-12-10	Zhang Xiaoyan Michelle	1.000	14,7599	83	177,1188	14.760
2021-12-10	FORMELA JEAN FRANCOIS	11.989	15,0300	999	180,3600	180.195

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

Transaktionshistorik

Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.

Fil Dato	Handle Dato	Form	Insider	Ticker	Sikkerhedstitel	Kode	Direkte	Dyrke motion Pris	Enhed Pris	Enheder Ændret	Værdi Ændret (1K)	Tilbage Muligheder	Tilbage Aktier
2026-04-20		3	Lally Robert B	IMA	Common Stock		D						58.778
2026-03-18	2026-03-16	4	Yarema Kristin	IMA	Common Stock	A - Award	D			85.400			85.400
2026-01-02	2025-12-30	4	Butler Erin	IMA	Common Stock	A - Award	D			22.500			25.551
2025-12-29	2025-12-24	4	SLATTERY JOSEPH P	IMA	Common Stock	P - Purchase	D		5,9900	16.000	96		16.000
2025-10-10	2025-07-25	4	Wang Stephen Hui By Magic Hat L.P.	IMA	Common Stock	A - Award	I			12.535			12.535
2025-10-10	2025-07-25	4	Wang Stephen Hui By Galaxy Alpha L.P.	IMA	Common Stock	A - Award	I			50.144			50.144
2025-10-10	2025-07-25	4	Wang Stephen Hui HLC Healthcare HK Limited	IMA	Common Stock	A - Award	I			188.042			188.042
2025-08-15	2025-07-25	4	Wang Jonathan Jian By Engene Inc.	IMA	Common Stock	A - Award	I			971.173			971.173
2025-08-15	2025-07-25	4	Wang Jonathan Jian	IMA	Common Stock	A - Award	D			143.832			143.832
2025-07-30	2025-07-25	4	ORBIMED ADVISORS LLC	IKNA	Common Stock	A - Award	I		2,4900	83.611	208		287.885
2025-07-30	2025-07-25	4	Bonita David P	IMA	Common Stock	P - Purchase	I		29,9000	83.611	2.500		287.885
2025-07-30	2025-07-25	4	Bonita David P	IMA	Common Stock	M - Exercise	D			379			379
2025-07-30	2025-07-25	4	Stampacchia Otello Omega Fund VI, L.P.	IMA	Common Stock	P - Purchase	I		29,9000	267.556	8.000		454.982
2025-07-30	2025-07-25	4	Stampacchia Otello	IMA	Common Stock	M - Exercise	D			379			379
2025-07-29	2025-07-28	4	Marango Jotin	IMA	Common Stock	F - Taxes	D		17,1600	-4.630	-79		11.146
2025-07-29	2025-07-28	4	Marango Jotin	IMA	Common Stock	A - Award	D			15.776			15.776
2025-07-29	2025-07-25	4	Butler Erin	IMA	Common Stock	A - Award	D			3.051			3.051
2023-09-21	2023-08-04	4/A	Bonita David P	IKNA	Non-Voting Common Stock	A - Award	I			153.121			5.582.144
2023-09-21	2023-08-04	4/A	ORBIMED ADVISORS LLC	IKNA	Non-Voting Common Stock	A - Award	I			153.121			5.582.144
2023-09-14	2023-08-04	4	ORBIMED ADVISORS LLC	IKNA	Common Stock	A - Award	I			153.121			2.251.218
2023-09-14	2023-08-04	4	Bonita David P	IKNA	Common Stock	A - Award	I			153.121			2.251.218
2022-06-24	2022-06-24	4	ORBIMED ADVISORS LLC See Footnotes	IKNA	Common Stock	P - Purchase	I		5,3700	-96.035	-516		2.098.097
2022-06-24	2022-06-24	4	ORBIMED ADVISORS LLC See Footnotes	IKNA	Common Stock	P - Purchase	I		4,3700	-65.965	-288		2.002.062
2022-06-24	2022-06-23	4	ORBIMED ADVISORS LLC See Footnotes	IKNA	Common Stock	P - Purchase	I		3,7100	-23.419	-87		1.936.097
2022-06-24	2022-06-22	4	ORBIMED ADVISORS LLC See Footnotes	IKNA	Common Stock	P - Purchase	I		3,5500	-66.806	-237		1.912.678
2022-06-24	2022-06-24	4	Bonita David P See Footnotes	IKNA	Common Stock	P - Purchase	I		5,3700	-96.035	-516		2.098.097
2022-06-24	2022-06-24	4	Bonita David P See Footnotes	IKNA	Common Stock	P - Purchase	I		4,3700	-65.965	-288		2.002.062
2022-06-24	2022-06-23	4	Bonita David P See Footnotes	IKNA	Common Stock	P - Purchase	I		3,7100	-23.419	-87		1.936.097
2022-06-24	2022-06-22	4	Bonita David P See Footnotes	IKNA	Common Stock	P - Purchase	I		3,5500	-66.806	-237		1.912.678
2022-04-25	2022-04-25	4	Marango Jotin	IKNA	Stock Option (Right to Buy)	A - Award	D	5,88		397.199		397.199
2022-02-04	2022-02-02	4	Zhang Xiaoyan Michelle	IKNA	Stock Option (Right to Buy)	A - Award	D	11,45		40.000		40.000
2022-02-04	2022-02-03	4	Manfredi Mark	IKNA	Stock Option (Right to Buy)	A - Award	D	9,76		238.900		238.900
2022-02-04	2022-02-02	4	Santillana Sergio L.	IKNA	Stock Option (Right to Buy)	A - Award	D	11,45		70.400		70.400
2022-02-04	2022-02-02	4	Ecsedy Jeffrey	IKNA	Stock Option (Right to Buy)	A - Award	D	11,45		59.360		59.360
2022-02-04	2022-02-02	4	Tessier Maude	IKNA	Stock Option (Right to Buy)	A - Award	D	11,45		40.000		40.000
2022-01-25	2022-01-21	4	Wooster Richard	IKNA	Stock Option (Right to Buy)	A - Award	D	11,06		29.200		29.200
2022-01-20	2022-01-18	4	Tessier Maude	IKNA	Stock Option (Right to Buy)	M - Exercise	D	4,51		-8.265		28.963
2022-01-20	2022-01-18	4	Tessier Maude	IKNA	Stock Option (Right to Buy)	M - Exercise	D	4,15		-24.606		11.186
2022-01-20	2022-01-18	4	Tessier Maude	IKNA	Stock Option (Right to Buy)	M - Exercise	D	2,94		-38.915		5.560
2022-01-20	2022-01-18	4	Tessier Maude	IKNA	Common Stock	M - Exercise	D		4,5100	8.265	37		100.578
2022-01-20	2022-01-18	4	Tessier Maude	IKNA	Common Stock	M - Exercise	D		4,1500	24.606	102		92.313
2022-01-20	2022-01-18	4	Tessier Maude	IKNA	Common Stock	M - Exercise	D		2,9400	38.915	114		67.707
2022-01-12	2022-01-11	4	Zhang Xiaoyan Michelle	IKNA	Stock Option (Right to Buy)	M - Exercise	D	2,15		-964		24.473
2022-01-12	2022-01-11	4	Zhang Xiaoyan Michelle	IKNA	Common Stock	S - Sale	D		12,0000	-964	-12		44.475
2022-01-12	2022-01-11	4	Zhang Xiaoyan Michelle	IKNA	Common Stock	M - Exercise	D		2,1462	964	2		45.439
2022-01-12	2022-01-10	4	Zhang Xiaoyan Michelle	IKNA	Stock Option (Right to Buy)	M - Exercise	D	2,15		-36		25.437
2022-01-12	2022-01-10	4	Zhang Xiaoyan Michelle	IKNA	Common Stock	S - Sale	D		12,0000	-36	-0		44.475
2022-01-12	2022-01-10	4	Zhang Xiaoyan Michelle	IKNA	Common Stock	M - Exercise	D		2,1462	36	0		44.511
2021-12-23	2021-12-21	4	Koehler Maria	IKNA	Stock Option (Right to Buy)	A - Award	D	14,92		13.419		13.419
2021-12-23	2021-12-21	4	FORMELA JEAN FRANCOIS	IKNA	Stock Option (Right to Buy)	A - Award	D	14,92		13.419		13.419
2021-12-23	2021-12-21	4	Stampacchia Otello	IKNA	Stock Option (Right to Buy)	A - Award	D	14,92		13.419		13.419
2021-12-23	2021-12-21	4	Dukes Iain D.	IKNA	Stock Option (Right to Buy)	A - Award	D	14,92		23.419		23.419
2021-12-23	2021-12-21	4	Renaud Ronald C JR	IKNA	Stock Option (Right to Buy)	A - Award	D	14,92		13.419		13.419
2021-12-23	2021-12-21	4	Bonita David P	IKNA	Stock Option (Right to Buy)	A - Award	D	14,92		13.419		13.419
2021-12-14	2021-12-10	4	Zhang Xiaoyan Michelle	IKNA	Stock Option (Right to Buy)	M - Exercise	D	2,15		-1.000		25.473
2021-12-14	2021-12-10	4	Zhang Xiaoyan Michelle	IKNA	Common Stock	S - Sale	D		14,7599	-1.000	-15		44.475
2021-12-14	2021-12-10	4	Zhang Xiaoyan Michelle	IKNA	Common Stock	M - Exercise	D		2,1462	1.000	2		45.475
2021-12-14	2021-12-14	4	FORMELA JEAN FRANCOIS	IKNA	Common Stock	S - Sale	I		14,0000	-5.959	-83		1.241.935
2021-12-14	2021-12-13	4	FORMELA JEAN FRANCOIS	IKNA	Common Stock	S - Sale	I		14,6400	-8.330	-122		1.247.894
2021-12-14	2021-12-10	4	FORMELA JEAN FRANCOIS	IKNA	Common Stock	S - Sale	I		15,0300	-11.989	-180		1.256.224
2021-12-14	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Common Stock	P - Purchase	I		16,0000	125.000	2.000		874.634
2021-12-14	2021-12-14	4	Atlas Venture Fund XI, L.P.	IKNA	Common Stock	S - Sale	D		14,0000	-5.959	-83		1.241.935
2021-12-14	2021-12-13	4	Atlas Venture Fund XI, L.P.	IKNA	Common Stock	S - Sale	D		14,6400	-8.330	-122		1.247.894
2021-12-14	2021-12-10	4	Atlas Venture Fund XI, L.P.	IKNA	Common Stock	S - Sale	D		15,0300	-11.989	-180		1.256.224
2021-12-14	2021-03-30	4	Atlas Venture Fund XI, L.P.	IKNA	Common Stock	P - Purchase	I		16,0000	125.000	2.000		874.634
2021-11-23	2021-11-22	4	Zhang Xiaoyan Michelle	IKNA	Stock Option (Right to Buy)	A - Award	D	13,75		176.699		176.699
2021-11-23		3	Zhang Xiaoyan Michelle	IKNA	Common Stock		D						44.475
2021-05-03	2021-04-15	4/A	Koehler Maria	IKNA	Stock Option (Right to Buy)	A - Award	D	18,45		26.838		26.838
2021-04-15	2021-04-15	4	Koehler Maria	IKNA	Stock Option (Right to Buy)	A - Award	D	18,45		26.838		26.838
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-42.614		0
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-157.288		0
2021-04-14	2021-03-30	4/A	Bonita David P See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-266.337		0
2021-04-14	2021-03-30	4/A	Bonita David P See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-983.054		0
2021-04-14	2021-03-30	4/A	Bonita David P See foonotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-653.277		0
2021-04-14	2021-03-30	4/A	Bonita David P See foonotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-2.411.260		0
2021-04-14	2021-03-30	4/A	Bonita David P See foonotes	IKNA	Series A Preferred Stock	C - Conversion	I			-551.259		0
2021-04-14	2021-03-30	4/A	Bonita David P See foonotes	IKNA	Series A Preferred Stock	C - Conversion	I			-2.034.708		0
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			157.288			157.288
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			5.429.023			5.429.023
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	48.400	774		91.014
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	375.000	6.000		1.845.872
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Common Stock	C - Conversion	I			42.614			42.614
2021-04-14	2021-03-30	4/A	Bonita David P See footnotes	IKNA	Common Stock	C - Conversion	I			1.470.872			1.470.872
2021-04-14	2020-12-21	4/A	Bonita David P See footnotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	1.430.103	2.000	1.430.103
2021-04-14	2020-12-21	4/A	Bonita David P See foonotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	8.938.148	12.500	8.938.148
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-42.614		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-157.288		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-266.336		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-983.055		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-653.277		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-2.411.260		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A Preferred Stock	C - Conversion	I			-551.259		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A Preferred Stock	C - Conversion	I			-2.034.708		0
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			157.288			157.288
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			5.429.023			5.429.023
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	48.400	774		91.014
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	375.000	6.000		1.845.872
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	C - Conversion	I			42.614			42.614
2021-04-13	2021-03-30	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	C - Conversion	I			1.470.872			1.470.872
2021-04-13	2020-12-21	4/A	ORBIMED ADVISORS LLC See footnotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	1.430.103	2.000	1.430.103
2021-04-13	2020-12-21	4/A	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	8.938.148	12.500	8.938.148
2021-04-01	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Series B Preferred Stock	C - Conversion	I			-5.362.888		0
2021-04-01	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Series A-2 Preferred Stock	C - Conversion	I			-7.863.094		0
2021-04-01	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-11.258.117		0
2021-04-01	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Series A Preferred Stock	C - Conversion	I			-9.499.999		0
2021-04-01	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Common Stock	C - Conversion	I			749.634			749.634
2021-04-01	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Common Stock	C - Conversion	I			1.099.118			1.268.213
2021-04-01	2021-03-30	4	FORMELA JEAN FRANCOIS	IKNA	Common Stock	C - Conversion	I			2.901.609			2.901.609
2021-04-01	2020-12-21	4	FORMELA JEAN FRANCOIS	IKNA	Series B Preferred Stock	A - Award	I		1,3985	5.362.888	7.500	5.362.888
2021-04-01	2021-03-30	4	Stampacchia Otello By Omega Fund VI, L.P.	IKNA	Series B Preferred Stock	C - Conversion	I			-12.870.933		0
2021-04-01	2021-03-30	4	Stampacchia Otello By Omega Fund VI, L.P.	IKNA	Common Stock	A - Award	I		16,0000	450.000	7.200		2.249.123
2021-04-01	2021-03-30	4	Stampacchia Otello By Omega Fund VI, L.P.	IKNA	Common Stock	C - Conversion	I			1.799.123			1.799.123
2021-04-01	2020-12-21	4	Stampacchia Otello By Omega Fund VI, L.P.	IKNA	Series B Preferred Stock	A - Award	I		1,3985	12.870.933	18.000	12.870.933
2021-04-01	2021-03-30	4	Atlas Venture Fund X, L.P.	IKNA	Series B Preferred Stock	C - Conversion	I			-5.362.888		0
2021-04-01	2021-03-30	4	Atlas Venture Fund X, L.P.	IKNA	Series A-2 Preferred Stock	C - Conversion	I			-7.863.094		0
2021-04-01	2021-03-30	4	Atlas Venture Fund X, L.P.	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-11.258.117		0
2021-04-01	2021-03-30	4	Atlas Venture Fund X, L.P.	IKNA	Series A Preferred Stock	C - Conversion	I			-9.499.999		0
2021-04-01	2021-03-30	4	Atlas Venture Fund X, L.P.	IKNA	Common Stock	C - Conversion	I			749.634			749.634
2021-04-01	2021-03-30	4	Atlas Venture Fund X, L.P.	IKNA	Common Stock	C - Conversion	I			1.099.118			1.268.213
2021-04-01	2021-03-30	4	Atlas Venture Fund X, L.P.	IKNA	Common Stock	C - Conversion	I			2.901.609			2.901.609
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-68.978		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-130.924		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-328.907		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series B Preferred Stock	C - Conversion	I			-920.484		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-806.752		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-2.257.785		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series A Preferred Stock	C - Conversion	I			-680.766		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Series A Preferred Stock	C - Conversion	I			-1.905.201		0
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			130.924			130.924
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			5.083.470			5.083.470
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	48.400	774		117.378
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	375.000	6.000		2.191.425
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Common Stock	C - Conversion	I			68.978			68.978
2021-04-01	2021-03-30	4	Bonita David P See footnotes	IKNA	Common Stock	C - Conversion	I			1.816.425			1.816.425
2021-04-01	2020-12-21	4	Bonita David P See footnotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	1.430.103	2.000	1.430.103
2021-04-01	2020-12-21	4	Bonita David P See footnotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	8.938.148	12.500	8.938.148
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-68.978		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-130.924		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-328.907		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	C - Conversion	I			-920.484		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-806.752		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A-1 Preferred Stock	C - Conversion	I			-2.257.785		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A Preferred Stock	C - Conversion	I			-680.766		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series A Preferred Stock	C - Conversion	I			-1.905.201		0
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			130.924			130.924
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See footnotes	IKNA	Non-Voting Common Stock	C - Conversion	I			5.083.470			5.083.470
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	48.400	774		117.378
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	P - Purchase	I		16,0000	375.000	6.000		2.191.425
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	C - Conversion	I			68.978			68.978
2021-04-01	2021-03-30	4	ORBIMED ADVISORS LLC See footnotes	IKNA	Common Stock	C - Conversion	I			1.816.425			1.816.425
2021-04-01	2020-12-21	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	1.430.103	2.000	1.430.103
2021-04-01	2020-12-21	4	ORBIMED ADVISORS LLC See foonotes	IKNA	Series B Preferred Stock	A - Award	I		1,3985	8.938.148	12.500	8.938.148
2021-03-25		3	Tessier Maude	IKNA	Common Stock		D						28.792
2021-03-25		3	Atlas Venture Associates Opportunity I, LLC	IKNA	Common Stock		I						169.095
2021-03-25		3	FORMELA JEAN FRANCOIS	IKNA	Common Stock		I						169.095

Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer

Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer

Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)

Konvertering af derivat

Salg eller overførsel af værdipapirer tilbage til virksomheden

Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet

Gave af værdipapirer af eller til insideren

Aktieswaps og lignende sikringstransaktioner

Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)

En transaktion rapporteret frivilligt på formular 4

Andet (ledsaget af en fodnote, der beskriver transaktionen)

IKNA / Ikena Oncology, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5